Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Lerodalcibep by LIB Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
Lerodalcibep is under clinical development by LIB Therapeutics and currently in Phase III for Heterozygous familial hypercholesterolemia (heFH). According to...
Data Insights
Lerodalcibep by LIB Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval
Lerodalcibep is under clinical development by LIB Therapeutics and currently in Phase III for Homozygous Familial Hypercholesterolemia (HoFH). According to...